# Royalty Pharma (RPRX) — Earnings

RPRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rprx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $1.32 |
| EPS estimate | $1.27 |
| EPS surprise | +3.82% |
| Revenue surprise | +1.85% |
| Revenue | $773.0M |
| Revenue estimate | $758.9M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1802768/000180276826000015/rprx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/5523f6c2-5bdc-3f75-5735-fd8dbd517d8c.html) |

Royalty Pharma reported Q2 2026 results on August 5, 2026. Earnings per share were $1.32, beating the $1.27 estimate by 3.82%. Revenue was $773.0 million against a $758.9 million consensus, a 1.85% beat. Compared with Q2 2025, EPS rose about 16% from $1.14 and revenue rose about 6% from $727.0 million.

Results in the table move around from quarter to quarter but trend higher. Annual EPS was $3.70 in 2022, $4.38 in 2023 and $4.01 in 2024, then rose 13% to $4.53 in 2025. The first half of 2026 added up to $2.62 per share, about 39% more than the $1.89 a year earlier. Q1 2023 set the EPS high in the table at $1.60, and revenue peaked at about $1.1 billion in Q4 2022 and Q1 2023. Royalty Pharma beat EPS estimates in 15 of the last 20 quarters, including the last five in a row.

The company reported Q3 between November 5 and November 10 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue stays above year-earlier levels, as it has in each of the last nine quarters.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $1.27 | $1.32 | 3.82% | $758.9M | $773.0M |
| Q1 2026 | May 6, 2026 | $1.11 | $1.30 | 17.30% | $881.7M | $925.0M |
| Q4 2025 | Feb 11, 2026 | $1.29 | $1.47 | 14.02% | $807.0M | $874.0M |
| Q3 2025 | Nov 5, 2025 | $0.99 | $1.17 | 18.08% | $717.4M | $814.0M |
| Q2 2025 | Aug 6, 2025 | $1.03 | $1.14 | 10.53% | $673.0M | $727.0M |
| Q1 2025 | May 8, 2025 | $0.95 | $0.75 | -21.40% | $705.3M | $839.0M |
| Q4 2024 | Feb 11, 2025 | $1.05 | $1.15 | 9.15% | $687.1M | $742.0M |
| Q3 2024 | Nov 6, 2024 | $0.93 | $0.92 | -1.09% | $696.9M | $735.0M |
| Q2 2024 | Aug 8, 2024 | $0.97 | $0.96 | -0.39% | $627.4M | $608.0M |
| Q1 2024 | May 9, 2024 | $0.99 | $0.98 | -0.92% | $665.6M | $717.0M |
| Q4 2023 | Feb 15, 2024 | $1.01 | $1.15 | 13.74% | $685.5M | $698.4M |
| Q3 2023 | Nov 8, 2023 | $0.77 | $0.79 | 2.50% | $631.7M | $637.0M |
| Q2 2023 | Aug 8, 2023 | $0.83 | $0.84 | 1.80% | $543.7M | $544.8M |
| Q1 2023 | May 9, 2023 | $1.27 | $1.60 | 25.85% | $902.0M | $1.1B |
| Q4 2022 | Feb 15, 2023 | $1.47 | $1.56 | 5.85% | $1.1B | $1.1B |
| Q3 2022 | Nov 8, 2022 | $0.71 | $0.73 | 2.45% | $586.3M | $597.0M |
| Q2 2022 | Aug 4, 2022 | $0.78 | $0.81 | 3.76% | $528.4M | $524.0M |
| Q1 2022 | May 5, 2022 | $0.73 | $0.60 | -18.00% | $597.0M | $604.9M |
| Q4 2021 | Feb 15, 2022 | $0.78 | $0.80 | 3.17% | $552.1M | $543.0M |
| Q3 2021 | Nov 10, 2021 | $0.70 | $0.73 | 3.71% | $563.1M | $586.9M |

## Frequently Asked Questions

### When did Royalty Pharma (RPRX) last report earnings?

Royalty Pharma last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did RPRX beat earnings estimates?

Yes. Royalty Pharma reported EPS of $1.32 for Q2 2026 against a $1.27 estimate — a 3.82% beat.

### How much revenue did RPRX report last quarter?

Royalty Pharma reported $773.0M in revenue for Q2 2026, against a consensus estimate of $758.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).